Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

Pretransplant NPM1 MRD testing significantly predicts relapse risk in acute myeloid leukemia.

Patients achieve a high 2-year survival and deep MRD-negative remissions with CAR T-cell therapy followed by stem cell transplant in B-cell ALL.

Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through either upfront intensive approaches or thoughtful sequential doublet therapies.

Panelists discuss how payer access challenges can determine whether patients receive therapy at all, with strategies including hospitalization for first cycles, advance prescription preparation, and recognition that oral regimens significantly impact quality of life for patients requiring lifelong treatment.

Research challenges age cut-offs in AML treatment, advocating for flexible, individualized approaches based on continuous age assessment.

The FDA approved ziftomenib for relapsed acute myeloid leukemia with NPM1 mutations, offering hope for high-risk patients.

Guideline adherence in treating acute lymphoblastic leukemia (ALL) enhances health care resource utilization, especially for adolescent and young adult patients.

The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations.

A novel combination therapy enhances the effectiveness of proteasome inhibitors against acute myeloid leukemia (AML), improving survival rates in preclinical models.

Panelists discuss how transplant eligibility has expanded beyond traditional intensive chemotherapy candidates to include patients receiving lower intensity regimens, with earlier transplant consultations and consideration of organ function preservation through less toxic induction approaches.

Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper infrastructure, while treatment decisions are based on intensive vs nonintensive therapy eligibility and specific genetic mutations like FLT3, IDH1, and TP53.

Panelists discuss how social determinants of health significantly impact AML care, particularly regarding transportation access, health literacy, and the intensive nature of treatment requiring frequent clinic visits for blood work and transfusions, which disproportionately affects patients living far from treatment centers.

A new drug application for Dasynoc, a lower-dose, bioequivalent formulation of dasatinib, was not approved for patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

Experts discuss the importance of initiating blinatumomab treatment for acute lymphoid leukemia in academic centers for optimal patient care.

Panelists discuss how the greatest unmet needs include addressing poor outcomes in specific subsets like TP53-mutant disease, managing the increasingly older population with secondary mutations, and ensuring global access to targeted therapies and next-generation sequencing.

Panelists discuss how fitness assessment has evolved beyond traditional age cutoffs to incorporate comprehensive geriatric assessments, frailty measures, and individualized evaluations, while questioning whether intensive therapy should automatically be given to fit patients given newer effective treatment options.

Panelists discuss how current risk stratification systems, particularly the European Leukemia Net 2022 classification for intensive therapy and the 2024 classification for lower intensity treatments, categorize patients based on complex cytogenetics and molecular features to guide prognosis and treatment selection.

Panelists discuss how the pathophysiology of acute myeloid leukemia has evolved from a single phenotype understanding to recognizing diverse genetic events that lead to transformation at the hematopoietic stem cell level, with treatment decisions now increasingly integrated with specific genetic mutations despite the disease’s rapid progression timeline.

High-risk patients who cannot find a matched sibling or matched unrelated donor may achieve a similar benefit from a haploidentical donor.

The evolving treatment landscape for unfit patients with newly diagnosed acute myeloid leukemia (AML) centers on venetoclax combination and personalized strategies.

Blood Cancer United, formerly Leukemia & Lymphoma Society, aims to enhance awareness and support for blood cancer patients during Blood Cancer Awareness Month.

Patients with acute myeloid leukemia (AML) in remission for over 3 years experience survival rates comparable with a matched cohort from the general population.

Ravi Vij, MD, MBA, discusses how measurable residual disease (MRD) testing is shaping treatment decisions in hematology and its potential to reduce costs and toxicity.

Race, ethnicity, and social factors can influence survival outcomes in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) receiving brexucabtagene autoleucel (brexu-cel).